Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.66 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.66 |
| ▸ | CHRNG | P07510 | 4/20 | 0.66 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.66 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.66 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.66 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.66 |
| ▸ | CHRND | Q07001 | 4/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.66 |
| ▸ | HRH1 | P35367 | 3/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.66 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10618419 | 0.98 | SLC6A2 (0.67) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL769850 | 0.83 | SLC6A3 (0.62) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL770168 | 0.81 | SLC6A3 (0.65) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL10470790 | 0.81 | SLC6A3 (0.59) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL770391 | 0.81 | SLC6A3 (0.67) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL769882 | 0.81 | SLC6A3 (0.70) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL26192588 | 0.81 | SLC6A3 (0.70) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL38777 | 0.80 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL770228 | 0.80 | SLC6A3 (0.71) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL12499296 | 0.80 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504640-B2 | Modified release formulations of a bupropion salt | VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L. (LU) | 2016-11-29 | — | — | US | disclosed |
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-07-23 | — | — | US | disclosed |
| US-8932628-B2 | Modified release formulations of a bupropion salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-01-13 | — | — | US | disclosed |
| US-8354453-B2 | Bupropion hydrobromide and therapeutic applications | VALEANT INTERNATIONAL BERMUDA (BM) | 2013-01-15 | — | — | US | disclosed |
| EP-2502621-A1 | Crystalline forms of bupropion HBr | Valeant International (Barbados) SRL (BB) | 2012-09-26 | — | — | EP | disclosed |
| EP-2474308-A1 | Pharmaceutical formulations containing bupropion hydrobromide | Valeant International (Barbados) SRL (BB) | 2012-07-11 | — | — | EP | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| US-20070276047-A1 | Administering bupropion hydrobromide to treat seasonal affective, obsessive compulsive, post-traumatic stress, psychological, respiratory system, attention deficit/hyperactivity, sexual or sleep disorders; anxiolytic agents, antidepressants; neurpathic pain, fibromyalgia, viricides; headaches, obesity | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-11-29 | — | — | US | disclosed |
| US-20070269516-A1 | Controlled release matrix | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-11-22 | — | — | US | disclosed |
| US-7241805-B2 | For therapy of depressive condition | BIOVAIL LABORATORIES, INC. (CA) | 2007-07-10 | — | — | US | disclosed |
| US-20070027213-A1 | For therapy of depressive condition | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (CA) | 2007-02-01 | — | — | US | disclosed |
| WO-2007002597-A2 | MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-01-04 | — | — | WO | disclosed |
| US-20050118286-A1 | Compositions and methods for treatment of nervous system disorders | CNS RESPONSE | 2005-06-02 | — | — | US | disclosed |
| US-20050096311-A1 | comprising an anticonvulsant and a neuroactive modulator; eg childhood disorders, cognitive disorders, substance disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders | CNS RESPONSE (US) | 2005-05-05 | — | — | US | disclosed |
| EP-0415613-B1 | Use of sertraline for the treatment of premature ejaculation | PFIZER (US) | 1994-09-07 | — | — | EP | disclosed |
| US-3885046-A | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression | BURROUGHS WELLCOME CO | 1975-05-20 | — | — | US | disclosed |
| US-3885046-A | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression | BURROUGHS WELLCOME CO | 1975-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | SLC6A2, SLC6A3, SLC6A11 | SLC6A3 2/4885SLC6A2 1/4885CHRNA1 308/4885 |
| US-20070276047-A1 | Administering bupropion hydrobromide to treat seasonal affective, obsessive compulsive, post-traumatic stress, psychological, respiratory system, attention deficit/hyperactivity, sexual or sleep disorders; anxiolytic agents, antidepressants; neurpathic pain, fibromyalgia, viricides; headaches, obesity | HCRTR2, HCRTR1, SLC6A2 | SLC6A3 11/4885SLC6A2 3/4885CHRNA1 784/4885 |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885CHRNA1 186/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885CHRNA1 186/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885CHRNA1 186/4885 |
| US-20070027213-A1 | For therapy of depressive condition | SLC6A2, SLC6A4, HTR5A | SLC6A3 4/4885SLC6A2 1/4885CHRNA1 144/4885 |
| US-20070269516-A1 | Controlled release matrix | SLC6A2, SLC6A11, SLC6A1 | SLC6A3 6/4885SLC6A2 1/4885CHRNA1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.